Annovis Bio Inc
ANVS
Company Profile
Business description
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Contact
101 Lindenwood Drive
Suite 225
MalvernPA19355
USAT: +1 484 875-3192
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,771.10 | 3.90 | -0.04% |
| CAC 40 | 7,683.73 | 58.51 | -0.76% |
| DAX 40 | 23,434.65 | 264.47 | -1.12% |
| Dow JONES (US) | 42,283.50 | 231.59 | -0.54% |
| FTSE 100 | 8,834.03 | 41.19 | -0.46% |
| HKSE | 23,980.30 | 80.69 | -0.34% |
| NASDAQ | 19,557.80 | 143.41 | -0.73% |
| Nikkei 225 | 38,536.74 | 225.41 | 0.59% |
| NZX 50 Index | 12,639.35 | 50.78 | -0.40% |
| S&P 500 | 5,992.92 | 40.19 | -0.67% |
| S&P/ASX 200 | 8,541.30 | 7.10 | -0.08% |
| SSE Composite Index | 3,387.40 | 1.32 | -0.04% |